"Microbiome research is expanding at a rapid pace and is improving our understanding of human health and disease. This is a fantastic time to be involved in microbiome research, and uBiome is positioned to make broad impacts in the field.” - Dr. Rowland, PhD
SAN FRANCISCO (PRWEB) January 18, 2019
uBiome, the leader in microbial genomics, announces the addition of Dr. Jennifer Rowland, PhD, Postdoctoral Research Fellow at the Finlay lab at the University of British Columbia, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Rowland will bring to uBiome expertise on the interaction of diet, microbes, and inflammation on DNA methylation. The appointment will help uBiome continue its advancement in human microbiome research.
“Dr. Rowland’s expertise in intestinal inflammation, gut permeability, and inefficient nutrient uptake and their relationship to microbiota and changes in DNA methylation patterns will be of great value to uBiome,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We welcome her to our scientific advisory board.”
Since 2014, Dr. Rowland has been a postdoctoral research fellow in the Finlay lab at the University of British Columbia (UBC) in Vancouver, Canada, which is focused on understanding how microbes interact with their host to cause health or disease. She completed her PhD at the University of Alabama at Birmingham in the lab of Dr. Michael Nierderweis investigating copper resistance mechanisms of Mycobacterium tuberculosis, the causative agent of TB. At UBC, Dr. Rowland is currently investigating how bacteria, pathogens, and beneficial microbes affect gene regulation and DNA methylation, which will provide insight into the long-term effects of changes to diet, resident gut microbiota, and inflammation on multiple tissues.
About joining uBiome's Scientific Advisory Board, Dr. Rowland said, “I’m excited to join the uBiome as an advisor and share my knowledge of bacterial-host interactions. Microbiome research is expanding at a rapid pace and is improving our understanding of human health and disease. This is a fantastic time to be involved in microbiome research, and uBiome is positioned to make broad impacts in the field.”
In addition to Dr. Rowland, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.